>>> For the latest QIDP list, please click HERE <<< Since our last QIDP blog from April 8, 2015, several new drugs have made the list which now includes 41 compounds. Below a table which includes compound, sponsor and development stage (Phase). It
Continue reading QIDP Drugs – 4th Edition
Posted in Recent Literature, The News |
Tagged Achaogen, Acorafloxacin, Actavis, Actavis/Furiex, Actelion Pharmaceuticals, AFN-1252, Amikacin + fosfomycin, antibiotic blog, AR-100, Aradigm Pharmaceuticals, ARD-3100/3150/1100, Arikace, Astellas, AstraZeneca / Entasis, Avarofloxacin, AZD-0914, BAL-30072, Basilea, BC-3781, BisEDT Antimicrobial Gel, Brilacidin, Cadazolid, carbavance, Cardeas Pharma, CB-315, CD-101, Ceftazidime + avibactam, Ceftolozane + tazobactam, Cellceutix Pharmaceuticals, CEM-101, CEM-102, Cempra Pharmaceuticals, Cidara Therapeutics, ciprofloxacin, Cubist, dalbavancin, Deb-1450, Deb-1452, Debiopharm Pharmaceuticals, delafloxacin, Durata Therapeutics, eravacycline, ETX-0914, FDA, finafloxacin, Fusidic Acid, iclaprim, Imipenem/cilastatin + MK-7655, Insmed Pharmaceuticals, isavuconazole, JNJ-Q2, lefamulin, ME-1100, Meiji Seika Pharma, Melinta Therapeutics, Merck, MerLion Pharmaceuticals, Meropenem + RPX7009, Microbion Corporation, minocycline, MK-4261, Motif, Nabriva Therapeutics, Nemonoxacin, nikkomycin, NikZ, omadacycline, OP-1068, oritavancin, Paratek Pharmaceuticals, plazomicin, PMX-30063, POL-7080, PTK-0796, QIDP drugs, QIDP list, QIDP list of antibiotics, Radezolid, RedHill Biopharma, relebactam, RHB-105, Roche / Polyphor, RPX2014, SCY-078, Scynexis Pharmaceuticals, secnidazole, SMT-19969, solithromycin, Summit plc, Surotomycin, SYM-1219, Symbiomix, TaiGen Biotechnology, Taigexyn, tedizolid, Tetraphase Pharmaceuticals, TG-873870, The Medicines Company, Torezolid, Trius, Valley Fever Solutions, WCK-2349, WCK-4873, WCK-771, Wockhardt, Wockhardt Pharmaceuticals |
Since the publication of a series of posters at ICAAC 2014, we finally know what’s hidden behind the ‘Carbavance’ name. ‘Carbavance’ stands for the combination of meropenem with the B-lactamase inhibitor RPX7009 which The Medicines Company (TMC) inlicensed from Rempex
Continue reading What’s in a Name? Would ‘Carbavance’ Still Smell as Sweet?
Posted in QIDP Antibiotics, The News, The Viewpoint |
Tagged AstraZeneca, AZ, biapenem, carbavance, FDA, meropenem, QIDP, Rempex, RPX2003, RPX2014, RPX7009, The Medicines Company, TMC |